Sunshine Total Assets from 2010 to 2025

SBFMW Stock

USD 0.24 0.01 2.00%

Sunshine Biopharma Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets are likely to outpace its year average in 2025. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2007-09-30

Previous Quarter

29.3 M

Current Value

30.1 M

Quarterly Volatility

11.8 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 148.9 K, Other Operating Expenses of 34.9 M or Total Operating Expenses of 15.8 M, as well as many indicators such as Price To Sales Ratio of 0.3, Dividend Yield of 0.0 or PTB Ratio of 0.34. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.

Check out the analysis of Sunshine Biopharma Correlation against competitors.

For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.

Latest Sunshine Biopharma's Total Assets Growth Pattern

Below is the plot of the Total Assets of Sunshine Biopharma Warrant over the last few years. Total assets refers to the total amount of Sunshine Biopharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Sunshine Biopharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Sunshine Biopharma's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sunshine Biopharma's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 27.35 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Sunshine Total Assets Regression Statistics

	Arithmetic Mean	7,936,268
	Geometric Mean	684,097
	Coefficient Of Variation	168.51
	Mean Deviation	11,164,525
	Median	673,261
	Standard Deviation	13,373,134
	Sample Variance	178.8T
	Range	33M
	R-Value	0.78
	Mean Square Error	76.3T
	R-Squared	0.60
	Significance	0.0004
	Slope	2,179,510
	Total Sum of Squares	2682.6T

Sunshine Total Assets History

	2025	33 M
	2024	31.4 M
	2023	27.3 M
	2022	29.2 M
	2021	2.2 M
	2020	1 M
	2019	98.1 K

Other Fundumenentals of Sunshine Biopharma

Intangibles To Total Assets

Sunshine Biopharma Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Net Receivables	Intangible Assets	Net Tangible Assets	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Good Will	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Investments
Total Assets		1.0	-0.98	-0.94	1.0	0.98	1.0	-0.31	0.21	0.99	0.78	0.78	-0.78	0.61	0.77	-0.68	1.0	0.9	-0.58	1.0	-0.68
Total Stockholder Equity	1.0		-0.98	-0.92	1.0	0.97	1.0	-0.31	0.17	0.99	0.78	0.78	-0.75	0.58	0.75	-0.68	1.0	0.88	-0.6	1.0	-0.68
Net Debt	-0.98	-0.98		0.93	-0.98	-0.96	-0.98	0.32	-0.28	-0.95	-0.73	-0.77	0.75	-0.6	-0.77	0.53	-0.99	-0.86	0.6	-0.98	0.53
Retained Earnings	-0.94	-0.92	0.93		-0.93	-0.97	-0.94	0.24	-0.36	-0.91	-0.81	-0.81	0.91	-0.78	-0.9	0.52	-0.93	-0.93	0.49	-0.94	0.52
Accounts Payable	1.0	1.0	-0.98	-0.93		0.98	1.0	-0.31	0.2	0.99	0.78	0.77	-0.77	0.6	0.75	-0.67	1.0	0.88	-0.58	1.0	-0.67
Total Liab	0.98	0.97	-0.96	-0.97	0.98		0.98	-0.28	0.35	0.95	0.75	0.78	-0.85	0.7	0.82	-0.63	0.98	0.91	-0.49	0.98	-0.63
Total Current Assets	1.0	1.0	-0.98	-0.94	1.0	0.98		-0.31	0.22	0.98	0.77	0.78	-0.78	0.62	0.77	-0.67	1.0	0.9	-0.57	1.0	-0.67
Common Stock	-0.31	-0.31	0.32	0.24	-0.31	-0.28	-0.31		-0.06	-0.3	-0.12	-0.38	0.36	-0.31	-0.36	0.18	-0.3	-0.36	0.31	-0.31	0.18
Short Term Debt	0.21	0.17	-0.28	-0.36	0.2	0.35	0.22	-0.06		0.06	-0.14	0.3	-0.41	0.41	0.43	0.21	0.25	0.31	-0.08	0.21	0.21
Net Receivables	0.99	0.99	-0.95	-0.91	0.99	0.95	0.98	-0.3	0.06		0.83	0.76	-0.75	0.57	0.73	-0.73	0.98	0.88	-0.57	0.99	-0.73
Intangible Assets	0.78	0.78	-0.73	-0.81	0.78	0.75	0.77	-0.12	-0.14	0.83		0.63	-0.69	0.64	0.75	-0.5	0.75	0.73	-0.41	0.78	-0.5
Net Tangible Assets	0.78	0.78	-0.77	-0.81	0.77	0.78	0.78	-0.38	0.3	0.76	0.63		-0.7	0.46	0.73	-0.48	0.78	0.87	-0.72	0.79	-0.48
Property Plant Equipment	-0.78	-0.75	0.75	0.91	-0.77	-0.85	-0.78	0.36	-0.41	-0.75	-0.69	-0.7		-0.92	-0.94	0.48	-0.77	-0.9	0.26	-0.79	0.48
Current Deferred Revenue	0.61	0.58	-0.6	-0.78	0.6	0.7	0.62	-0.31	0.41	0.57	0.64	0.46	-0.92		0.92	-0.25	0.6	0.73	-0.13	0.63	-0.25
Long Term Debt	0.77	0.75	-0.77	-0.9	0.75	0.82	0.77	-0.36	0.43	0.73	0.75	0.73	-0.94	0.92		-0.33	0.76	0.9	-0.39	0.79	-0.33
Good Will	-0.68	-0.68	0.53	0.52	-0.67	-0.63	-0.67	0.18	0.21	-0.73	-0.5	-0.48	0.48	-0.25	-0.33		-0.65	-0.62	0.36	-0.68	1.0
Net Invested Capital	1.0	1.0	-0.99	-0.93	1.0	0.98	1.0	-0.3	0.25	0.98	0.75	0.78	-0.77	0.6	0.76	-0.65		0.89	-0.58	1.0	-0.65
Short Long Term Debt	0.9	0.88	-0.86	-0.93	0.88	0.91	0.9	-0.36	0.31	0.88	0.73	0.87	-0.9	0.73	0.9	-0.62	0.89		-0.54	0.91	-0.62
Capital Stock	-0.58	-0.6	0.6	0.49	-0.58	-0.49	-0.57	0.31	-0.08	-0.57	-0.41	-0.72	0.26	-0.13	-0.39	0.36	-0.58	-0.54		-0.58	0.36
Net Working Capital	1.0	1.0	-0.98	-0.94	1.0	0.98	1.0	-0.31	0.21	0.99	0.78	0.79	-0.79	0.63	0.79	-0.68	1.0	0.91	-0.58		-0.68
Short Term Investments	-0.68	-0.68	0.53	0.52	-0.67	-0.63	-0.67	0.18	0.21	-0.73	-0.5	-0.48	0.48	-0.25	-0.33	1.0	-0.65	-0.62	0.36	-0.68

Click cells to compare fundamentals

About Sunshine Biopharma Financial Statements

Sunshine Biopharma investors use historical fundamental indicators, such as Sunshine Biopharma's Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Sunshine Biopharma. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	31.4 M	33 M
Intangibles To Total Assets	0.06	0.06

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC